
Mulhuddart, Dublin 15 CMC Lead Established Products
Astellas Pharma Inc. · Mulhuddart, Dublin 15, IE
Applications are made on Astellas Pharma Inc.'s own site. We never sit in the middle.
Job description
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at Astellas.com . Are you driven to make a real difference in the lives of patients? We're seeking passionate individuals who thrive in dynamic environments, embrace new ideas, and aren't afraid to take intelligent risks. People who act with unwavering integrity and are deeply committed to making a tangible impact. Working Environment and Location • This position is to be based in Dublin. • At Astellas we recognize the importance of work/life balance, and we are proud to offer a hybrid working solution allowing time to connect with colleagues at the office with the flexibility to also work from home. We believe this will optimize the most productive work environment for all employees to succeed and deliver. Hybrid work from certain locations may be permitted in accordance with Astellas’ Responsible Flexibility Guidelines. Purpose and Scope • This role works within a cross-functional Asset Maximization Team and is accountable for the CMC activities supporting the end-to-end advancement and VALUE maximization of one or more in-market assets. • The CMC leader serves as the single, integrated voice for CMC product development, manufacturing and supply within the Asset Maximization Team, while also shaping asset strategy, driving alignment across assets and with enterprise goals, and ensuring high-quality execution across product development, manufacturing, regulatory, quality, supply chain, commercial, finance, and external partner workstreams. • The role translates scientific, technical, operational, and business complexity into clear strategic options, risk-based recommendations, and executable plans that maximize patient impact, portfolio VALUE, and speed to decision. This role is acting as the primary CMC interface to Astellas Ireland Co., Ltd. (AICL). • This role defines and delivers globally aligned CMC strategy ensuring optimal formulation, manufacturability, supply reliability, and COGM. This position will also translate complexity into strategic options, risks, and business implications for AICL and governance decision-making. Role and Responsibilities 1. Strategy and Asset Leadership a. Define, own and implement the integrated CMC asset strategy, ensuring alignment with commercial and regulatory strategy, lifecycle objectives as well as AICL product strategy. b. Serve as the primary product development, manufacturing and supply representative on the asset maximization team, providing strategic input into asset plans, governance decisions, investment choices, and differentiating VALUE creation opportunities. c. Holds accountability for the product strategy and product innovation ensuring alignment with the quality target product profile (QTPP) and lifecycle objectives d. Accountable for managing and optimizing COGM to enhance product VALUE, profitability, and lifecycle sustainability e. Translate complex scientific, technical, CMC regulatory, quality, manufacturing, supply chain, and commercial considerations into clear options, trade-offs, and implications for timelines, cost, quality, risk, and asset VALUE. 2. Integrated Execution and Delivery a. Lead the cross-functional Product VALUE Team, integrating drug substance, drug product, analytical, CMC regulatory, quality, manufacturing, supply chain, finance, intellectual property and external partner workstreams. b. Convert the integrated CMC asset strategy into fit-for-purpose integrated plans with clear milestones, dependencies, resource requirements, budget assumptions, risk mitigation pathways, and decision points. c. Lead the manufacturing site selection ensuring alignment with commercialization plans as well as with the PDM Supply Network Strategy. d. Maintain clear end-to-end accountability for the overall control strategy including integrated CMC risk management of the asset across the patient axis in accordance with ICH Q8-Q11 principles and enterprise criteria e. Drive delivery of phase-appropriate CMC development strategies consistent with Asset Maximization Team goals, regulatory expectations, launch readiness, and enterprise portfolio priorities. f. Manage integrated CMC and asset-level budget and resource forecasts in partnership with functional leaders, ensuring disciplined prioritization and investment quality. Continue:Role and Responsibilities 3. Regulatory, Quality, and Technical Integrity a. Co-develop CMC regulatory strategy in close partnership with CMC regulatory, representing CMC perspectives in health authority meetings and pre-submission interactions. b. Ensure CMC activities, integrated control strategy, submission content, product risk assessments, and regulatory filing roadmaps are scientifically robust, phase-appropriate, compliant, and aligned to quality expectations. c. Maintain accountability for the quality, completeness, and strategic coherence of CMC submission content, including Module 3 and equivalent regional requirements. 4. Governance, Stakeholder Alignment, and Enterprise VALUE a. Serve as the primary CMC interface to decision making bodies such as AICL International Business Executive Management committee (AICL IB EM), governance bodies, senior leaders, and alliance governance; present concise recommendations, decision options, risks, and implications for asset VALUE to AMT, AICL IB EM and AICL Board. b. Drive alignment across functions, geographies, regions, and partners by eliminating silos, accelerating decision-making, and ensuring consistent execution against the integrated strategy. c. Anticipate and resolve cross-functional risks and issues, escalating transparently through governance when decisions, resources, or trade-offs are required. d. Represent the asset or program externally with alliance partners, CDMOs, vendors, regulators, key experts, and relevant stakeholder communities, ensuring credible, compliant, and consistent communication. 5. Capability Development a. Contribute to developing enterprise capability by mentoring POD and VALUE team members, strengthening team effectiveness, and embedding high standards for execution, governance, quality, and VALUE creation and delivery. b. Partner with functional leaders to support growth, development, and readiness of team members contributing to asset and product development outcomes. Candidate Profile • Strategic enterprise integrator: Connects scientific, clinical, technical, operational, regulatory, manufacturing, quality, commercial, and financial considerations into a coherent and integrated CMC strategy that advances assets and maximizes portfolio VALUE. • Credible CMC leader: Brings deep CMC and development credibility, with the judgment to challenge assumptions, guide fit-for-stage decisions, and connect technical choices to downstream regulatory, manufacturing, launch, and lifecycle implications. • Enterprise operator with business judgment: Combines disciplined execution, financial stewardship, risk management, and governance readiness with the ability to make timely, high-quality trade-offs under uncertainty. • Influential collaborator and communicator: Builds alignment across functions, geographies, and partner ecosystems; influences without authority; and communicates with clarity, credibility, and executive presence at senior levels. Essential Qualifications • Advanced degree in sciences, engineering, pharmaceutical sciences, or a related discipline; doctoral-level training preferred. • Relevant experience commensurate with a PhD, MS, or BS, including significant experience leading complex, global, matrixed commercialized drug programs or strategic developmen
Other jobs you might want
Astellas Pharma Inc.
Process Engineer
17470
Astellas Pharma Inc.
Warsaw OTC Finance Operations Analyst, EMEA With German 00 844
Warsaw, PL, 00-844
Astellas Pharma Inc.
Munich MSL BY 80992
Warum Astellas Pharma / About Astellas Warum Astellas Pharma
Astellas Pharma Inc.
Levallois Peret Medical And Clinical Manager, Lung Cancer Portfolio 92300
Levallois-Peret, FR, 92300
Astellas Pharma Inc.
Warsaw Manager, Quality Document Management 00 844
Warsaw, PL, 00-844
Astellas Pharma Inc.
Quality Assurance For Integrated Batch Release 12 Month FTC
17237